CONTACT
+91 80 2808 2808
info@biocon.com
About Us
Overview
Who we are
Our Key Priorities
Board of Directors
Key Management Team
Our Legacy
Fact Sheet
Our Stories
Scientific Publications
Awards & Recognition
Products
Overview
Key Therapeutic Areas
Generics
Biosimilars
Novel Biologics
Branded Formulations
Businesses
Overview
Generics
Executive Leadership Team
API
Generic Formulations
Quality & Compliance
Manufacturing Operations
Research & Development
Regulatory Affairs
Biosimilars
Biocon Biologics
Board of Directors
Executive Leadership Team
Global Portfolio
Wide Global Footprint
Quality & Compliance
Partners
Global Scale Manufacturing
Research & Development
Branded Formulations
Novel Biologics
Biocon and Novels
Novels Pipeline
Research Services
Investors
Overview
Financial Fact Sheet
Financial Information
Annual Reports
Quarterly Reports
Key Figures (Annual & Quarterly)
Earnings Call Recordings
Earnings Call Transcripts
Subsidiary Financials
Investor Presentations
Corporate Governance
Overview
Board of Directors
Board Committees
Our Leadership
Corporate Structure
Company History & Milestones
Governance Documents & Policies
Share Information
Share Graph
Share Series
Share Price Look Up
Investment Calculator
Share Price Alerts
Fragulizer
Dividends
Unclaimed and Unpaid Dividend
IEPF
Shareholder Services
Annual General Meeting
Postal Ballot
Investor Feedback
Investor FAQ
Miscellaneous Communication
Financial Calendar
Stock Exchange Disclosures
Notice of Board Meeting
Investors Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements & Disclosures
Analyst Coverage
Code Of Conduct
Email Subscription Services
Investor Contact
Disclosures under Regulation 46 of LODR
Careers
Overview
Working With Us
Now Hiring
Functions
Our Culture
Diversity And Inclusion
Learning & Development
Awards & Recognition
Benefits
Meet Our Employees
Career FAQ’s
Responsibility
Overview
Biocon Foundation
Social Impact
Partners
Grant-in-Aid
Awards and Recognition
Sustainability
Safer Workplace
An Environment of Change
Environmental Clearance
EHS Certifications
Biocon Academy
News
Overview
Press Releases
Company Statements
Media Stories
Image Gallery
Video Gallery
Events & Calendar
Media Contacts
More+
Contact Us
Blog
For Patients
Biocon in Malaysia
Group Companies
Syngene
Biocon BIologics
Bicara
Biocon Academy
Biocon
/
Investor Relations
/
Stock Exchange Disclosures
/
Press Release
PRESS RELEASE
STOCK EXCHANGE DISCLOSURES
Notice of Board Meeting
Investor Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements and Disclosures
FY 2023-24
May-23
23-May
Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
April-23
25-Apr
Serum & Biocon Biologics Agree to Restructure Equity Investment
05-Apr
Biocon Academy Conducted Graduation Ceremony For 185 Students across Four Programs
04-Apr
Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments
FY 2022-23
March-23
28-Mar
Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
February-23
14-Feb
Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
January-23
24-Jan
Biocon Foundation Wins the Prestigious ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022
December-22
22-Dec
Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
14-Dec
Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India
05-Dec
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Novermber-22
29-Nov
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
24-Nov
Biocon Limited enters into a commercialization agreement with Zentiva in Europe
14-Nov
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
11-Nov
Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
October-22
31-Oct
Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine
17-Oct
Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
07-Oct
Biocon Foundation Receives ‘Mahatma Award 2022 for Excellence in Social Good’
September-22
24-Sep
Kiran Mazumdar-Shaw Awarded with H.K. Firodia Lifetime Achievement Award 2022 for Excellence in Science & Technology
August-22
05-Aug
Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
July-22
27-July
Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%; Biosimilars Up 29%; Generics Up 19%; Research Services Up 8%
June-22
09-June
University of Glasgow officially Opens Mazumdar Shaw Advance Research Centre
May-22
19-May
Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
April-22
28-Apr
Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9% Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr. FY22 Revenue at Rs 8,397 Cr, Up 14%; Core EBITDA Up 18% at Rs 2,669 Cr; PBT (before Exceptional Item) at Rs 1094 Cr, Up 4%
26-Apr
Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
01-Apr
Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion
FY 2021-22
March-22
29-Mar
University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
23-Mar
Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
February-22
27-Feb
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
January-22
20-Jan
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
December-21
30-Dec
Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
23-Dec
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
07-Dec
Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East
01-Dec
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
November-21
16-Nov
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
15-Nov
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
October-21
21-Oct
Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
21-Oct
Appointment of Dr. Eric Vivek Mazumdar as Non-Executive, Non-Independent Director of the Company
21-Oct
Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
04-Oct
Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US
September-21
16-Sep
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
July-21
29-July
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
26-July
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
22-July
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
April-21
29-Apr
Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr. FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.
28-Apr
Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
FY 2020-21
Mar-21
29-Mar
Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
02-Mar
Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
01-Mar
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
01-Mar
Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Feb-21
16-Feb
Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
04-Feb
Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia
Jan-21
21-Jan
Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
21-Jan
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
07-Jan
Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Dec-20
28-Dec
Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
15-Dec
Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Nov-20
07-Nov
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion
Oct-20
30-Oct
Biocon Ranked Among Top 5 Biotech Employers Globally
22-Oct
Press Release on financial results for the Quarter ended September 30, 2020
08-Oct
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Sep-20
22-Sep
Biocon appoints Anupam Jindal as its Chief Financial Officer
Aug-20
31-Aug
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-Aug
Disclosure of material impact of COVID 19 pandemic on the Company
03-Aug
Execution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
Jul-20
31-Jul
Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-Jul
Press Release on financial results for the quarter ended June 30, 2020.
21-Jul
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-Jul
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Jun-20
22-Jun
Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-Jun
Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-Jun
Kiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-Jun
Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
May-20
27-May
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-May
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-May
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
Apr-20
28-Apr
Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
14-Apr
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-Apr
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
ARCHIVES
FY: From April 1 – March 31
Know more
about us
>> Generics
>> Biocon Academy
>> Biocon Malaysia
NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION